Trikafta is Vertex’s triple-combination CFTR modulator for cystic fibrosis, taken as two tablets in the morning and one at night. It is among the most expensive chronic oral medicines sold in the United States, and unlike most drugs covered on this site, there is genuinely nothing to shop.
That is the honest framing of this page. There is no generic, no authorized generic, no compounded version, no cash-pay pharmacy that carries it cheaper, and no manufacturer coupon that an uninsured person can use. A guide that pretends otherwise would waste your time. What follows is the real number, where it comes from, and the three routes that actually change what you pay. Everything was researched September 4, 2026.
What Does Trikafta Cost Without Insurance?
Vertex publishes its own list prices to satisfy a Connecticut disclosure law, and that document is the most authoritative price available. As of its July 2026 effective date, the wholesale acquisition cost of Trikafta is $29,057.52 for a 28-day supply, and the figure is identical for every presentation: the 100/50/75 mg and 50/25/37.5 mg tablet therapy packs and both oral granule packs for younger children.
Drugs.com quotes a cash retail price of $28,391.28 for the same 28-day pack, about 2% below Vertex’s list. CMS’s Medicare Part D spending file gives the third read: across 27,275 Trikafta claims in 2024, Medicare paid an average of $26,570.46 per claim and $265,266.91 per beneficiary for the year, on total spending of $724.7 million.
| Cost item | Low | Typical | High |
|---|---|---|---|
| Trikafta, one 28-day supply | $28,391 | $28,724 | $29,058 |
| Trikafta, one year at 13 fills | $369,087 | $373,417 | $377,748 |
| Medicare’s average payment per Trikafta claim, 2024 | $26,570 | $26,570 | $26,570 |
| Medicare spending per Trikafta patient, full year 2024 | $265,267 | $265,267 | $265,267 |
| Alyftrek (Vertex’s newer once-daily triple), 28-day supply | $29,058 | $29,058 | $29,058 |
| Kalydeco (ivacaftor alone), 28-day supply | $29,058 | $29,058 | $29,058 |
| Orkambi, 28-day supply | $23,773 | $23,773 | $23,773 |
| Symdeko, 28-day supply | $25,456 | $25,456 | $25,456 |
| Generic or authorized generic Trikafta | none | none | none |
| Vertex GPS co-pay card, commercial insurance required | $0 | $0 | $0 |
The 2024 CMS figures are a year and a half older than the list price, which is why they sit lower. They are worth showing anyway, because they confirm that this is a price real payers actually pay rather than a sticker everyone discounts away.
What Drives the Price
There is no generic, and the near-term pipeline is blocked
FDA’s Drugs@FDA records show elexacaftor only under Vertex’s own two applications, NDA 212273 and NDA 217660, with no other company listed. The only ivacaftor generics in those records at all are two Lupin applications, and both sit at tentative approval, meaning FDA has cleared them on the merits but patent or exclusivity protection blocks marketing. There is no authorized generic either: FDA’s Listing of Authorized Generics, current as of July 2, 2026, has no entry for elexacaftor, ivacaftor, Trikafta or Kalydeco.
The newer modulator did not lower the ceiling
Alyftrek, Vertex’s once-daily vanzacaftor/tezacaftor/deutivacaftor triple, was approved December 20, 2024 per FDA records. On Vertex’s July 2026 disclosure it is priced identically to Trikafta at $29,057.52 per 28-day supply, and Kalydeco carries the same figure. A newer product from the same manufacturer did not create price competition, it created a matching price, so a switch will not lower your bill.
The drug never touches a retail pharmacy
CMS’s National Average Drug Acquisition Cost survey, which is the usual benchmark for what pharmacies pay, has no row for Trikafta. We queried it September 4, 2026 using both the “starts with” and “contains” operators, and also for elexacaftor, Alyftrek, Kalydeco, Orkambi and Symdeko. All six returned zero rows. NADAC surveys retail pharmacy acquisition, and Vertex distributes these products through a limited specialty network, so the file that would normally give a cash payer a floor simply does not cover them.
Dosing is fixed, so there is no lower dose to ask about
Trikafta is dosed as a fixed therapy pack sized to a 28-day cycle. There is no half-strength option that costs less per month, no 90-day discount and no split-fill economics. Thirteen 28-day fills is a year, and the year is the unit of cost.
The list price rises on Vertex’s schedule
Vertex’s disclosure document is stamped with a July 2026 effective date and a June 2026 revision. That is the file to re-check, not a news article about it, because the figure moves when Vertex revises it and nothing else about the market forces it down.
Cash Price vs. Insurance
On most pages here, we can point to a situation where paying cash beats using insurance. Trikafta is not one of them. At roughly $29,000 a month, no self-pay discount, discount card or pharmacy comparison closes a gap that size. The two September 2026 prices above, Vertex’s list and the cash retail figure, span about 2%.
The manufacturer’s savings program does not help either, and it is important to read the terms rather than the headline. The Vertex GPS Co-pay Assistance Program can lower a copay to as little as $0 per fill, but its own footnote states that annual assistance is capped at $20,000 and that it is “not available to individuals with government-funded insurance such as Medicaid, Medicare, and TRICARE.” It applies only to people who already have private commercial insurance and a copay to reduce. A $20,000 cap against a $378,000 annual price also means the card runs out inside the first month for anyone whose plan puts Trikafta on coinsurance.
Vertex does run a separate patient assistance program for people with no insurance or prescription coverage. What it does not do is publish the terms. Its patient-facing site answers the question “What if I lose my insurance or cannot afford my medicine?” by saying Vertex “may offer programs to help” and directing you to call a support specialist at 1-877-752-5933. There is no published income threshold, no application form on the site and no stated award. That is a real gap for anyone trying to plan, and the only way to resolve it is the phone call.
How to Pay Less
Call Vertex GPS and ask specifically about the patient assistance program, not the copay card. They are different programs with opposite eligibility. The copay card needs commercial insurance. The assistance program is for people who have none. Ask for the income threshold, the documentation list and the turnaround time in writing.
Get coverage before you get a bill. This is the single highest-value action on this page. Medicaid eligibility, a marketplace plan during open enrollment or a special enrollment period, or a parent’s plan up to age 26 all convert a six-figure annual cost into a capped out-of-pocket maximum. A CF diagnosis often qualifies someone for a special enrollment period after a life change, so do not assume you have to wait.
Use CF Foundation Compass before you make any decision. It is a free, one-on-one case management service from the Cystic Fibrosis Foundation, available regardless of income or insurance status, reachable at 1-844-266-7277. Its case managers compare insurance plans side by side, appeal denials and refer to assistance programs. They do not give out money, but they know which programs are currently accepting patients, which changes month to month.
Check foundation fund status the day you apply, not the week before. As of September 4, 2026 the HealthWell Foundation’s Cystic Fibrosis Treatments fund and its Cystic Fibrosis Vitamins and Supplements fund are both closed to new patients for lack of funding. HealthWell states that existing grants continue through their 12-month cycle and that closed funds reopen when replenished. These grants cover copays and coinsurance for insured patients, so they were never a cash-payer solution, but they matter enormously once you do have coverage.
Do not let an uncovered fill go to collections without asking about assistance first. If you have already been billed for Trikafta by a specialty pharmacy or a hospital-owned pharmacy, the same tactics that work on any large medical bill apply. See our guides to negotiating medical bills and hospital charity care, and use free and sliding-scale clinics to keep the rest of your CF care affordable while you sort the drug out.
Budget the rest of the CF regimen separately. Modulator therapy is the largest line but not the only one. Inhaled therapies, airway clearance and enzymes add up, and our guides to inhaler costs and Nucala costs cover how respiratory drug pricing works when a specialty pharmacy is involved.
The Bottom Line
Trikafta is $28,391 to $29,058 per 28-day supply and there is no version of shopping that changes it. The number that matters is not the price, it is your coverage status, because coverage is the only thing standing between a $378,000 sticker and a capped annual out-of-pocket. If you are uninsured, the sequence is Vertex GPS patient assistance, then Medicaid or the marketplace, then CF Foundation Compass to work the appeals. Use our fair price tool to sanity-check any quote you are given, and expect these figures to move when Vertex revises its list-price disclosure.